CancerRadarCancerRadar
Tyrosine kinase inhibitorFDA-approvedSecond-line

Lapatinib

How it works

Blocks the growth signals that stimulate the growth and division of cancer cells.

Cancer types

Breast Cancer— HER2-positive
Pancreatic Cancer— HER2-positive
Ovarian Cancer— HER2-positive

Efficacy

Lapatinib has been shown to improve response rates in HER2-positive ovarian cancer patients, with a median overall survival of approximately 16 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

StudyCancer typeStageEfficacy
Understanding Lapatinib Resistance in HER2+ Breast CancerBreast Cancerlab-study—Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.